Charles River Labs (CRL) Stock Forecast & Price Target

Compare

576 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRL Analyst Ratings

Moderate Buy

8 Buy

4 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Charles

River Labs

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$212.80

▼(-3.14% Downside)

Based on 12 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $212.80 with a high forecast of $265.00 and a low forecast of $170.00. The average price target represents a -3.14% change from the last price of $219.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"$115","266":"$266","152.75":"$152.8","190.5":"$190.5","228.25":"$228.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$265.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":212.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$212.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,152.75,190.5,228.25,266],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.48,204.51999999999998,209.56,214.6,219.64,224.68,229.72,234.76,239.8,244.84,249.88,254.92000000000002,259.96,{"y":265,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.48,200.50461538461536,201.52923076923076,202.55384615384614,203.57846153846154,204.6030769230769,205.6276923076923,206.6523076923077,207.6769230769231,208.70153846153846,209.72615384615386,210.75076923076924,211.7753846153846,{"y":212.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.48,197.2123076923077,194.9446153846154,192.67692307692306,190.40923076923076,188.14153846153846,185.87384615384616,183.60615384615383,181.33846153846153,179.07076923076923,176.80307692307693,174.5353846153846,172.2676923076923,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":184.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.31,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":145.99,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":116.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.09,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$265.00

Average Price Target$212.80

Lowest Price Target$170.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick B Donnelly

Citi

$265

Buy

20.62%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Molina Healthcare (NYSE: MOH)

Eric Coldwell

Robert W. Baird

$224→$231

Buy

5.14%

Upside

Reiterated

01/13/26

Charles River price target raised to $231 from $224 at BairdCharles River price target raised to $231 from $224 at Baird

Michael Ryskin

Bank of America Securities

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Charles River Labs (NYSE: CRL) and Butterfly Network (NYSE: BFLY)

Max Smock

William Blair

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Option Care Health (NASDAQ: OPCH)

Elizabeth Anderson CFA

Evercore ISI

$250→$260

Buy

18.34%

Upside

Reiterated

01/13/26

Charles River price target raised to $260 from $250 at Evercore ISICharles River price target raised to $260 from $250 at Evercore ISI

Ann Hynes

Mizuho Securities

$200→$215

Hold

-2.14%

Downside

Reiterated

01/09/26

Charles River price target raised to $215 from $200 at MizuhoCharles River price target raised to $215 from $200 at Mizuho

Luke Sergott

Barclays

$215

Buy

-2.14%

Downside

Reiterated

01/09/26

Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Charles River Labs (CRL)

Casey Woodring

J.P. Morgan

$165→$190

Hold

-13.52%

Downside

Reiterated

12/15/25

Charles River price target raised to $190 from $165 at JPMorganCharles River price target raised to $190 from $165 at JPMorgan

David Toung

Argus Research

$200

Buy

-8.97%

Downside

Upgraded

11/17/25

Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus

Patrick Wood

Morgan Stanley

$170→$185

Hold

-15.79%

Downside

Reiterated

11/11/25

Charles River price target raised to $185 from $170 at Morgan StanleyCharles River price target raised to $185 from $170 at Morgan Stanley

Charles Rhyee

TD Cowen

$205→$197

Buy

-10.33%

Downside

Reiterated

11/10/25

Buy Rating for Charles River Labs: Potential Upside Amid Dynamic Environment and Favorable Trends

Dan Leonard

UBS

$170

Hold

-22.62%

Downside

Reiterated

11/06/25

UBS Remains a Hold on Charles River Labs (CRL)

David Windley

Jefferies

$142→$195

Buy

-11.24%

Downside

Upgraded

09/08/25

Charles River upgraded to Buy from Hold at JefferiesCharles River upgraded to Buy from Hold at Jefferies

Justin Bowers

Deutsche Bank

$180→$185

Buy

-15.79%

Downside

Reiterated

08/07/25

Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)

Unknown Analyst

CFRA

Not Ranked

CFRA

$165

Hold

-24.90%

Downside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick B Donnelly

Citi

$265

Buy

20.62%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Molina Healthcare (NYSE: MOH)

Eric Coldwell

Robert W. Baird

$224→$231

Buy

5.14%

Upside

Reiterated

01/13/26

Charles River price target raised to $231 from $224 at BairdCharles River price target raised to $231 from $224 at Baird

Michael Ryskin

Bank of America Securities

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Charles River Labs (NYSE: CRL) and Butterfly Network (NYSE: BFLY)

Max Smock

William Blair

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Option Care Health (NASDAQ: OPCH)

Elizabeth Anderson CFA

Evercore ISI

$250→$260

Buy

18.34%

Upside

Reiterated

01/13/26

Charles River price target raised to $260 from $250 at Evercore ISICharles River price target raised to $260 from $250 at Evercore ISI

Ann Hynes

Mizuho Securities

$200→$215

Hold

-2.14%

Downside

Reiterated

01/09/26

Charles River price target raised to $215 from $200 at MizuhoCharles River price target raised to $215 from $200 at Mizuho

Luke Sergott

Barclays

$215

Buy

-2.14%

Downside

Reiterated

01/09/26

Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Charles River Labs (CRL)

Casey Woodring

J.P. Morgan

$165→$190

Hold

-13.52%

Downside

Reiterated

12/15/25

Charles River price target raised to $190 from $165 at JPMorganCharles River price target raised to $190 from $165 at JPMorgan

David Toung

Argus Research

$200

Buy

-8.97%

Downside

Upgraded

11/17/25

Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus

Patrick Wood

Morgan Stanley

$170→$185

Hold

-15.79%

Downside

Reiterated

11/11/25

Charles River price target raised to $185 from $170 at Morgan StanleyCharles River price target raised to $185 from $170 at Morgan Stanley

Charles Rhyee

TD Cowen

$205→$197

Buy

-10.33%

Downside

Reiterated

11/10/25

Buy Rating for Charles River Labs: Potential Upside Amid Dynamic Environment and Favorable Trends

Dan Leonard

UBS

$170

Hold

-22.62%

Downside

Reiterated

11/06/25

UBS Remains a Hold on Charles River Labs (CRL)

David Windley

Jefferies

$142→$195

Buy

-11.24%

Downside

Upgraded

09/08/25

Charles River upgraded to Buy from Hold at JefferiesCharles River upgraded to Buy from Hold at Jefferies

Justin Bowers

Deutsche Bank

$180→$185

Buy

-15.79%

Downside

Reiterated

08/07/25

Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)

Unknown Analyst

CFRA

Not Ranked

CFRA

$165

Hold

-24.90%

Downside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

3 Months

xxx

Success Rate

26/42 ratings generated profit

Average Return

+4.71%

upgraded a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +4.71% per trade.

1 Year

David WindleyJefferies

Success Rate

33/42 ratings generated profit

Average Return

+14.81%

upgraded a buy rating 4 months ago

Copying David Windley's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +14.81% per trade.

2 Years

xxx

Success Rate

33/42 ratings generated profit

Average Return

+21.97%

upgraded a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +21.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRL has received 19 Buy Ratings, 27 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the past 3 months is 212.80.

Each month's total comprises the sum of three months' worth of ratings.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $2.35 with a range of $2.25 to $2.44. The previous quarter’s EPS was $2.43. CRL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $987.23M with a range of $977.11M to $1.00B. The previous quarter’s sales results were $1.00B. CRL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.

CRL Stock Forecast FAQ

What is CRL’s average 12-month price target, according to analysts?

Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 212.80.

What is CRL’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CRL, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRL a Buy, Sell or Hold?

Charles River Laboratories Intl has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.

What is Charles River Laboratories Intl’s price target?

The average price target for Charles River Laboratories Intl is 212.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $265.00 ,the lowest forecast is $170.00. The average price target represents -3.14% Decrease from the current price of $219.7.

What do analysts say about Charles River Laboratories Intl?

Charles River Laboratories Intl’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CRL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Charles River Labs (CRL) Stock Forecast & Price Target

CRL Analyst Ratings

CRL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Charles River Labs

CRL Analyst Recommendation Trends

CRL Financial Forecast

CRL Earnings Forecast

CRL Sales Forecast

CRL Stock Forecast FAQ

Detailed List of Analyst Forecasts